New standard for describing marker genes

Tuesday, 30 November, 2010

The Genomic Standards Consortium (GSC), an international community of scientists, published a new standard for describing marker genes with their Minimum Information about an ENvironmental Sequence (MIENS). Published online on 11/16/10 in Nature Precedings (Yilmaz et al), the paper is available at http://dx.doi.org/10.1038/npre.2010.5252.2.

The goal of the Genomics Standards Consortium is to promote standardisations of the description of genomes and the exchange and integration of genomic data. With the development of the MIENS specification, GSC’s goal has been extended to marker genes.

The adoption of phylogenetic marker genes as molecular proxies for tracking and cataloguing the diversity of microorganisms has revolutionised the way we view the biological world and provided us with insights into how life has evolved and how different organisms are genetically related to each other.

The paper defines all of the different phylogenetic and functional genes (or gene fragments) as ‘marker genes’ as they are used to profile natural genetic diversity across the Tree of Life. With powerful next-generation sequencing, the GSC is revising standards for new marker genes to add contextual data for epidemiology and health studies to monitor the origins and regional spreading of pandemics and to study the variation of the human microbiota.

A specific focus of the extended requirements are the sets of measurements and observations describing particular habitats, termed ‘environmental packages’. By adopting MIENS - ‘living checklists’ - scientists are enhancing our ability to analyse natural genetic diversity across the Tree of Life as it is currently being documented.

Related News

QIMR Berghofer signs strategic partnership with Nakanoshima Qross

QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

To lead the commercialisation of Vaxxas's proprietary high‑density microarray patch (HD‑MAP)...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd